Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04427787
Title A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA)
Acronym LOLA
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.